Evidence map›Paper›PMID 26158894›Full record

Trial reportSleep2015

Modafinil Increases Awake EEG Activation and Improves Performance in Obstructive Sleep Apnea during Continuous Positive Airway Pressure Withdrawal.

David Wang, Xiao Xue Bai, Shaun C Williams, Shu Cheng Hua, Jong-Won Kim, Nathaniel S Marshall, Angela D'Rozario, Ronald R Grunstein

Open access · bronzeAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Sleep, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.1field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 22 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Investigation and management of residual sleepiness in CPAP-treated patients with obstructive sleep apnoea: the European view.European respiratory review : an official journal of the European Respiratory Society · 2022
    Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Role ofFrontiers in molecular neuroscience · 2017
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 2 countries.

David WangSleep and Circadian Group, Woolcock Institute of Medical Research, University of Sydney, Australia.
Xiao Xue BaiSleep and Circadian Group, Woolcock Institute of Medical Research, University of Sydney, Australia.
Shaun C WilliamsSleep and Circadian Group, Woolcock Institute of Medical Research, University of Sydney, Australia.
Shu Cheng HuaThe First Hospital of Jilin University, China.
Jong-Won KimCentre for Integrated Research and Understanding of Sleep (CIRUS), Australia.
Nathaniel S MarshallSleep and Circadian Group, Woolcock Institute of Medical Research, University of Sydney, Australia.
Angela D'RozarioSleep and Circadian Group, Woolcock Institute of Medical Research, University of Sydney, Australia.
Ronald R GrunsteinSleep and Circadian Group, Woolcock Institute of Medical Research, University of Sydney, Australia.
University of Sydney · AUJilin University · CNRoyal Prince Alfred Hospital · AUSydney Local Health District · AUWoolcock Institute of Medical Research · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesWe examined the changes in waking electroencephalography (EEG) biomarkers with modafinil during continuous positive airway pressure (CPAP) withdrawal in patients with obstructive sleep apnea (OSA) to investigate neurophysiological evidence for potential neurocognitive improvements.

designRandomized double-blind placebo-controlled crossover study. CPAP was used for the first night and then withdrawn for 2 subsequent nights. Each morning after the 2 CPAP withdrawal nights, patients received either 200 mg modafinil or placebo. After a 5-w washout, the procedure repeated with the crossover drug. SETTINGS: University teaching hospital.

participantsStable CPAP users (n = 23 men with OSA). MEASUREMENT AND

resultsKarolinska Drowsiness Test (KDT) (awake EEG measurement with eyes open and closed), Psychomotor Vigilance Task (PVT), and driving simulator Performance were assessed bihourly during the 3 testing days following CPAP treatment and CPAP withdrawal nights. Compared to placebo, modafinil significantly increased awake EEG activation (faster EEG frequency) with increased alpha/delta (A/D) ratio (P < 0.0001) and fast ratio = (alpha+beta)/(delta+theta) (P < 0.0001) across the 2 days of CPAP withdrawal. The A/D ratio significantly correlated with the driving simulator response time (P = 0.015), steering variation (P = 0.002), and PVT reaction time (P = 0.006). In contrast, individual EEG band power of alpha, beta, theta, and delta did not correlate with any neurocognitive performance.

conclusionsModafinil administration during continuous positive airway pressure (CPAP) withdrawal increased awake EEG activation, which correlated to improved performance. This study provides supporting neurophysiological evidence that modafinil is a potential short-term treatment option during acute CPAP withdrawal.

Indexed as

Continuous Positive Airway PressureAttentionAutomobile DrivingBenzhydryl CompoundsBiomarkersCross-Over StudiesDouble-Blind MethodElectroencephalographyHumansMaleMiddle AgedModafinilReaction TimeSleep Apnea, ObstructiveSleep StagesWakefulnessBenzhydryl CompoundsBiomarkersModafinilbrainwave activityEEG frequencyEEG spectramotor vehicle accidentneurobehavioral performanceneurocognitive functionsleep apnea

Identifiers

PMID26158894
PMCPMC4507735
OpenAlexW2415229641

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.